Sign in
Taking people in United StatesPhase 2

NAV-240 for adults with moderate-to-severe hidradenitis suppurativa

Tests NAV-240 against placebo in adults with moderate-to-severe hidradenitis suppurativa.

Key facts

Who runs it
Navigator Medicines, Inc.
Where
Boston, Maitland, Miami, Murray, North Miami Beach, Phoenix, Portsmouth, Ridgeland, Scottsdale, Tamarac, Tampa, and The Bronx, United StatesSee the 14 sitesAlso in 7 other countries, 32 sites
Registry title
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
Status
Recruiting
Phase
Phase 2
People taking part
150 people, planned
Started
5 Jan 2026
Expected to end
Oct 2027
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • NAV-240
  • Placebo to match NAV-240
Record updated
22 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with moderate-to-severe hidradenitis suppurativa (HS), a long-lasting skin disease with painful lumps, whose disease did not improve enough with antibiotics.

Age
18 to 70 years
Sex
All sexes
Disease stage
Stable HS for ≥ 2 months. At least 5 abscesses and inflamed lumps. Inflamed areas in at least 2 body regions, one at Hurley Stage II or III.
Earlier treatment
At least one course of antibiotics that did not help enough. Doxycycline, minocycline or tetracycline by mouth is allowed at a stable dose until Week 16.
Biomarker or test result
Women who can become pregnant need a negative pregnancy test.

Main reasons for not taking part

  • More than 20 draining tunnels (channels under the skin that leak fluid)
  • Major surgery, including HS surgery, within 12 weeks before Day 1
  • HIV, hepatitis B or hepatitis C, or active or latent tuberculosis (TB)
  • Alcohol or drug abuse in the past 2 years, or a positive urine drug test
  • Past cancer (except some fully treated skin cancers or localized carcinoma in situ), moderate to severe heart failure, or immune deficiency

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Diagnosis of stable HS for ≥ 2 months
  • Abscesses and Inflammatory Nodules (lesion) count ≥ 5
  • Inflammatory HS lesions in at least 2 different body regions, one of which must be Hurley Stage II or III
  • Inadequate response to at least one course of antibiotics
  • Topical antiseptics/washes are not required but allowed. If in use, the participant must agree to use one single product consistently through Week 16
  • Use of oral antibiotics is allowed during the study under the following conditions: the dose and regimen must remain stable until Week 16. Allowed oral antibiotics include doxycycline, minocycline, or tetracycline
  • Female participants of childbearing potential must have a negative pregnancy test
  • Participants of reproductive potential must use a highly effective method of contraception

Who cannot take part

  • Active skin disease (bacterial, fungal, viral infection) that, in the opinion of the Investigator, could interfere with assessment of HS or requires treatment with antibiotic(s) also used to treat HS
  • Has had major surgery, including HS surgery, within 12 weeks prior to Day 1
  • A positive urine drug screen at Screening
  • History of alcohol or drug abuse within the past 2 years
  • History or evidence of human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus (HCV), or a positive test at Screening
  • History or current diagnosis of active or latent pulmonary or extrapulmonary TB infection or a positive test at Screening
  • History of moderate to severe heart failure or recent (within past 6 months) cerebrovascular accident, myocardial infarction, or coronary stenting
  • Any history of malignancy (including lymphoma and leukemia) other than a successfully treated and considered cured non-metastatic cutaneous squamous cell carcinoma, basal cell carcinoma or localized carcinoma in situ
  • History of immune deficiency
  • > 20 draining tunnel count

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

Also in 7 other countries, 32 sites

  • Beth Israel Deaconess Medical CenterBoston, United StatesContact: Associate Director, Clinical OperationsTaking people
  • Accel Research Sites NetworkMaitland, United StatesContact: Associate Director, Clinical OperationsTaking people
  • Cordova Research InstituteMiami, United StatesContact: Associate Director, Clinical OperationsTaking people
  • Floridian Research InstituteMiami, United StatesContact: Associate Director, Clinical OperationsTaking people
  • Kentucky Advanced Medical Research LLCMurray, United StatesContact: Associate Director, Clinical OperationsTaking people
  • Ziaderm Research LLCNorth Miami Beach, United StatesContact: Associate Director, Clinical OperationsTaking people
  • Medical Dermatology SpecialistPhoenix, United StatesContact: Associate Director, Clinical OperationsTaking people
  • StracSkin, PLLCPortsmouth, United StatesContact: Associate Director, Clinical OperationsTaking people
  • Sky Integrative Medical CenterRidgeland, United StatesContact: Associate Director, Clinical OperationsTaking people
  • Scottsdale Clinical TrialsScottsdale, United StatesContact: Associate Director, Clinical OperationsTaking people
  • FWD Clinical ResearchTamarac, United StatesContact: Associate Director, Clinical OperationsTaking people
  • MplusM - D&H Tamarac Research CenterTamarac, United StatesContact: Associate Director, Clinical OperationsTaking people
  • ForCare Clinical ResearchTampa, United StatesContact: Associate Director, Clinical OperationsTaking people
  • Equity Medical, LLCThe Bronx, United StatesContact: Associate Director, Clinical OperationsTaking people

About the trial

What the trial wants to find out

The main objective of this study is to determine if NAV-240 works more effectively than a dummy treatment (placebo) for participants with moderate-to-severe HS. The main endpoint of this study is the percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 16, meaning at least a 75% reduction in inflamed skin bumps (abscess and inflammatory nodule (AN) count) with no increase in number of abscesses or draining tunnels (channels under the skin that leak fluid or pus) compared to the baseline (start of the study).

Read full original descriptionShow less

Participants will:

* Receive NAV-240 dose 1, NAV-240 dose 2 or placebo as a drip into the veins (intravenous infusion). * Visit the clinic up to 9 times for checkups and tests over 22 weeks. * Complete a daily diary about their skin pain.

The 3 groups in the trial

  • NAV-240 Dose 1Treatment being tested

    Treatment: NAV-240

  • NAV-240 Dose 2Treatment being tested

    Treatment: NAV-240

  • PlaceboPlacebo, for comparison

    Treatment: Placebo to match NAV-240

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study of NAV-240 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa
Plain-language title
NAV-240 for adults with moderate-to-severe hidradenitis suppurativaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07384975, who can take part
Record updated
22 July 2026